Literature DB >> 34928174

Mathematical evaluation of post-radiotherapy salivary gland function using salivary gland scintigraphy.

Tomohiro Itonaga1, Koichi Tokuuye1, Ryuji Mikami1, Akira Shimizu2, Hiroki Sato2, Mana Yoshimura1, Kiyoaki Tsukahara2, Kazuhiro Saito1.   

Abstract

OBJECTIVE: Xerostomia is the most common treatment-related toxicity after radiotherapy (RT) for head and neck carcinoma, reducing the quality of life of patients due to a decrease in salivary gland function.
METHODS: Salivary gland scintigraphy was performed to quantitatively evaluate the salivary gland functions in patients undergoing RT. It was done chronologically for 62 salivary glands of 31 patients before RT and retested 12 months later.
RESULTS: The salivary gland functions of most patients deteriorated post-RT and recovered when the radiation dose to the salivary gland was not high. The mean dose to the salivary gland was found to be the most reliable factor in deteriorating salivary gland function, and the tolerance dose was determined to be 46 Gy. The recovery rate of salivary gland function after 1 year of RT was 72% in the RT alone group (n = 10), 56% in the conformal radiotherapy group (n = 15), and 44% in the bioradiotherapy group (n = 6).
CONCLUSION: Scintigraphy revealed that the salivary glands recovered from post-RT hypofunction when decreased doses were administered. The determined tolerance dose of 46 Gy may guide the approach to minimizing associated xerostomia in RT. ADVANCES IN KNOWLEDGE: In this study, the average tolerated dose to the salivary glands was 46 Gy.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34928174      PMCID: PMC8822577          DOI: 10.1259/bjr.20210718

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  23 in total

1.  Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer.

Authors:  A Eisbruch; R K Ten Haken; H M Kim; L H Marsh; J A Ship
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-10-01       Impact factor: 7.038

2.  Quantitative dose-volume response analysis of changes in parotid gland function after radiotherapy in the head-and-neck region.

Authors:  J M Roesink; M A Moerland; J J Battermann; G J Hordijk; C H Terhaard
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-11-15       Impact factor: 7.038

Review 3.  A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact.

Authors:  S B Jensen; A M L Pedersen; A Vissink; E Andersen; C G Brown; A N Davies; J Dutilh; J S Fulton; L Jankovic; N N F Lopes; A L S Mello; L V Muniz; C A Murdoch-Kinch; R G Nair; J J Napeñas; A Nogueira-Rodrigues; D Saunders; B Stirling; I von Bültzingslöwen; D S Weikel; L S Elting; F K L Spijkervet; M T Brennan
Journal:  Support Care Cancer       Date:  2010-03-25       Impact factor: 3.603

4.  Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy.

Authors:  Angel I Blanco; K S Clifford Chao; Issam El Naqa; Gregg E Franklin; Konstantin Zakarian; Milos Vicic; Joseph O Deasy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-07-15       Impact factor: 7.038

5.  A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results.

Authors:  K S Chao; J O Deasy; J Markman; J Haynie; C A Perez; J A Purdy; D A Low
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-03-15       Impact factor: 7.038

6.  Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer.

Authors:  A Eisbruch; H M Kim; J E Terrell; L H Marsh; L A Dawson; J A Ship
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-07-01       Impact factor: 7.038

7.  Parotid gland function after radiotherapy: the combined michigan and utrecht experience.

Authors:  Tim Dijkema; Cornelis P J Raaijmakers; Randall K Ten Haken; Judith M Roesink; Pètra M Braam; Anette C Houweling; Marinus A Moerland; Avraham Eisbruch; Chris H J Terhaard
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-01-07       Impact factor: 7.038

8.  Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

Authors:  James A Bonner; Paul M Harari; Jordi Giralt; Roger B Cohen; Christopher U Jones; Ranjan K Sur; David Raben; Jose Baselga; Sharon A Spencer; Junming Zhu; Hagop Youssoufian; Eric K Rowinsky; K Kian Ang
Journal:  Lancet Oncol       Date:  2009-11-10       Impact factor: 41.316

9.  Preservation of parotid function with uncomplicated conformal radiotherapy.

Authors:  Annelies Maes; Caroline Weltens; Patrick Flamen; Philippe Lambin; Ria Bogaerts; Xuan Liu; Jan Baetens; Robert Hermans; Walter Van den Bogaert
Journal:  Radiother Oncol       Date:  2002-05       Impact factor: 6.280

10.  Parotid gland sparing IMRT for head and neck cancer improves xerostomia related quality of life.

Authors:  C M van Rij; W D Oughlane-Heemsbergen; A H Ackerstaff; E A Lamers; A J M Balm; C R N Rasch
Journal:  Radiat Oncol       Date:  2008-12-09       Impact factor: 3.481

View more
  2 in total

1.  Assessment of salivary gland function after 177Lu-PSMA radioligand therapy: Current concepts in imaging and management.

Authors:  Sonia Mahajan; Ravinder K Grewal; Kent P Friedman; Heiko Schöder; Neeta Pandit-Taskar
Journal:  Transl Oncol       Date:  2022-05-03       Impact factor: 4.803

Review 2.  Diagnosis, Prevention, and Treatment of Radiotherapy-Induced Xerostomia: A Review.

Authors:  Yanli Li; Xuehan Li; Runxuan Pang; Guang Yang; Mingxu Tian; Tengyu Zhao; Yunhan Sun; Eui-Seok Lee; Heng Bo Jiang; Jianmin Han
Journal:  J Oncol       Date:  2022-08-27       Impact factor: 4.501

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.